@article{36bf853bf22347bf8e5c66b3a7e3cd84,
title = "Reconciling Antimicrobial Susceptibility Testing and Clinical Response in Antimicrobial Treatment of Chronic Cystic Fibrosis Lung Infections",
abstract = "Median cystic fibrosis (CF) survival has increased dramatically over time due to several factors, including greater availability and use of antimicrobial therapies. During the progression of CF lung disease, however, the emergence of multidrug antimicrobial resistance can limit treatment effectiveness, threatening patient longevity. Current planktonic-based antimicrobial susceptibility testing lacks the ability to predict clinical response to antimicrobial treatment of chronic CF lung infections. There are numerous reasons for these limitations including bacterial phenotypic and genotypic diversity, polymicrobial interactions, and impaired antibiotic efficacy within the CF lung environment. The parallels to other chronic diseases such as non-CF bronchiectasis are discussed as well as research priorities for moving forward.",
keywords = "antimicrobial susceptibility, cystic fibrosis",
author = "Waters, {Valerie J.} and Kidd, {Timothy J.} and Rafael Canton and Ekkelenkamp, {Miquel B.} and Johansen, {Helle Krogh} and Lipuma, {John J.} and Bell, {Scott C.} and Elborn, {J. Stuart} and Flume, {Patrick A.} and Vandevanter, {Donald R.} and Peter Gilligan and Wendy Bullington and Burgel, {Pierre Regis} and Catherine Byrnes and Pavel Drevinek and Alison Holmes and Barbara Kahl and Holly Maples and Stacey Martiniano and Susanna McColley and Andrew Morris and Marianne Muhlebach and Michael Parkins and Felix Ratjen and Jason Roberts and Lisa Saiman and Anand Shah and Alan Smyth and Ranjani Somayaji and Giovanni Taccetti and Michael Tunney and Kevin Winthrop and Edith Zemanick",
note = "Funding Information: Financial support. This work was supported by the European Cystic Fibrosis Society, Cystic Fibrosis Foundation, Cystic Fibrosis Trust, Cystic Fibrosis Canada, and Cystic Fibrosis Australia. Funding Information: Potential conflicts of interest. V. J. W. has received honoraria from Novartis Canada and Teva Pharmaceutical Industries and grants from Novartis Canada, Innovotech Inc, and Gilead outside the submitted work. S. C. B. has received grants from Vertex Pharma and has served on advisory boards for Vertex Pharma, Galapagos, and AbbVie outside the submitted work. J. S. E. has received grants from Vertex Pharma and Novartis, and has served on advisory boards for Vertex Pharma, AbbVie, and Celtaxsys. P. A. F. received grants from the European Cystic Fibrosis Society, Cystic Fibrosis Foundation, Cystic Fibrosis Trust, Cystic Fibrosis Canada, and Cystic Fibrosis Australia during the conduct of the study, and has also received grants from Bayer Healthcare, Insmed, and Novoteris and personal fees from Bayer Healthcare AG, Insmed, Eloxx Pharmaceuticals, and Horizon Pharma outside the submitted work. J. J. L. has received personal fees from Aradigm, CURx, Horizon, Raptor, and VAST Therapeutics outside the submitted work. R. C. has received personal fees from Chiesi Spain, Pfizer, and Merck Sharp & Dohme outside the submitted work. D. R. V. has received personal fees from AbbVie, Albumedix, AN2 Therapeutics Inc, Aradigm, Calithera, Chiesi USA, Concert, CURx, Eloxx, Enbiotix, Genentech, Horizon, IBF Biotechnics, ICON Clinical Sciences, Ionis, Kala, Life Science Strategies, OrbiMed, Protalix, PTC Therapeutics, Pulmocide, Raptor, Recida, Respirion, Savara, VAST, and Vertex outside the submitted work. All other authors report no potential conflicts of interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.",
year = "2019",
month = nov,
day = "15",
doi = "10.1093/cid/ciz364",
language = "English (US)",
volume = "69",
pages = "1812--1816",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "10",
}